MBL2 and aspergillosis: Kaur et al. [46] demonstrated that recombinant MBL treatment of mice with pulmonary aspergillosis increased the levels of tumor necrosis factor (TNF)-α and IL-1α and significantly decreased IL-10, enhancing survival and reducing the fungal burden.